The best magazine
Conclusion
This study provides valuable insight into the community management of mRCC in Italy. The efficacy and safety of sorafenib in the first- and second-line settings in everyday clinical practice for treating metastatic mRCC patients were similar to those reported in prospective clinical trials. The median OS of 16.3 months in the second-line setting in this study was similar to the 16.6 months median OS reported in the sorafenib arm of the recent prospective, Phase III INTORSECT trial.
Source: ...